Answers are grounded in this paper and cite their sources.
The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one‐size‐fits‐all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K inhibitors? The report by Soumerai et al. of zandelisib with zanubrutinib in follicular and mantle cell lymphoma is an important addition to the data. Commentary on: Soumerai et al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. Br J Haematol 2024;204:1762‐1770.
No takes yet. Share an insight, caveat, or question.
Martynchyk et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: